GGrantIndex
← Leaderboards

Nola M. Hylton

University Of California, San Francisco

Google Scholar ↗PubMed ↗ORCID ↗
$19,153,972
Attributed
$22,312,387
Total exposure
12
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$40,456,001 · 13

By mechanism

P01$20,932,226 · 3
R01$13,210,362 · 4
U01$5,976,469 · 2
U54$316,544 · 1
P41$20,400 · 3

Top collaborators

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Magnetic Resonance Imaging”

Research focus

Magnetic Resonance ImagingImageResponseNeoadjuvant TherapyMalignant Breast NeoplasmBreastTumorBaseChemotherapyClinical TrialsTreatment ResponseProgramsMeasurementDiffusion Magnetic Resonance ImagingAmerican College Of Radiology Imaging NetworkPredictive ModelingPerformanceEvaluationDesignMolecularProtocols DocumentationTechnologyResearch PersonnelRecurrence

Grant awards (62)

The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes$2,747,550
P01 · FY2025 · CA
Project 2: Non-invasive imaging metrics to optimize early treatment switching decisions and prognostic modeling of long-term outcomes$358,572
P01 · FY2025 · CA · contact PI
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes$2,641,849
P01 · FY2024 · CA
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy$556,346
R01 · FY2024 · CA · contact PI
Project 2: Non-invasive imaging metrics to optimize early treatment switching decisions and prognostic modeling of long-term outcomes$335,380
P01 · FY2024 · CA · contact PI
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes$2,689,478
P01 · FY2023 · CA
Project 2: Non-invasive imaging metrics to optimize early treatment switching decisions and prognostic modeling of long-term outcomes$375,951
P01 · FY2023 · CA · contact PI
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$626,049
U01 · FY2022 · CA · contact PI
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy$578,246
R01 · FY2022 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$1,800,771
P01 · FY2021 · CA
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$649,765
U01 · FY2021 · CA · contact PI
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy$580,052
R01 · FY2021 · CA · contact PI
Project 02 - Non-invasive imaging metrics for determining non-response$337,968
P01 · FY2021 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$1,845,433
P01 · FY2020 · CA
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$652,814
U01 · FY2020 · CA · contact PI
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy$582,942
R01 · FY2020 · CA · contact PI
Project 02 - Non-invasive imaging metrics for determining non-response$339,057
P01 · FY2020 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$1,954,475
P01 · FY2019 · CA
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$627,280
U01 · FY2019 · CA · contact PI
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy$601,146
R01 · FY2019 · CA · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials$468,077
R01 · FY2019 · CA · contact PI
Project 02 - Non-invasive imaging metrics for determining non-response$330,029
P01 · FY2019 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$2,124,555
P01 · FY2018 · CA
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$662,868
U01 · FY2018 · CA · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials$483,603
R01 · FY2018 · CA · contact PI
Project 02 - Non-invasive imaging metrics for determining non-response$341,377
P01 · FY2018 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$2,339,503
P01 · FY2017 · CA
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials$487,259
R01 · FY2017 · CA · contact PI
Project 02 - Non-invasive imaging metrics for determining non-response$370,278
P01 · FY2017 · CA · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials$497,317
R01 · FY2016 · CA · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials$515,599
R01 · FY2015 · CA · contact PI
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$506,332
U01 · FY2015 · CA · contact PI
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$515,713
U01 · FY2014 · CA · contact PI
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$516,330
U01 · FY2013 · CA · contact PI
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$583,574
U01 · FY2012 · CA · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-operative Treatment Trials$451,782
R01 · FY2012 · CA · contact PI
Quantitative Imaging for Assessing Breast Cancer Response to Treatment$635,744
U01 · FY2011 · CA · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-operative Treatment Trials$454,587
R01 · FY2011 · CA · contact PI
ACRIN 6657: CONTRAST-ENHANCED BREAST CANCER MRI FOR EVALUATION OF PATIENTS$7,564
P41 · FY2011 · RR · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-operative Treatment Trials$471,263
R01 · FY2010 · CA · contact PI
Anatomic and Biologic Staging of Breast Disease with MRI$457,084
R01 · FY2010 · CA · contact PI
MRI For Staging DCIS and Assessing Response to Treatment$420,830
R01 · FY2010 · CA · contact PI
ACRIN 6657: CONTRAST-ENHANCED BREAST CANCER MRI FOR EVALUATION OF PATIENTS$6,418
P41 · FY2010 · RR · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-operative Treatment Trials$481,560
R01 · FY2009 · CA · contact PI
Anatomic and Biologic Staging of Breast Disease with MRI$448,122
R01 · FY2009 · CA · contact PI
MRI For Staging DCIS and Assessing Response to Treatment$414,681
R01 · FY2009 · CA · contact PI
ACRIN 6657: CONTRAST-ENHANCED BREAST CANCER MRI FOR EVALUATION OF PATIENTS$6,418
P41 · FY2009 · RR · contact PI
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-operative Treatment Trials$482,956
R01 · FY2008 · CA · contact PI
Anatomic and Biologic Staging of Breast Disease with MRI$434,608
R01 · FY2008 · CA · contact PI
MRI For Staging DCIS and Assessing Response to Treatment$413,528
R01 · FY2008 · CA · contact PI
Anatomic and Biologic Staging of Breast Disease with MRI$432,136
R01 · FY2007 · CA · contact PI
MRI For Staging DCIS and Assessing Response to Treatment$403,658
R01 · FY2007 · CA · contact PI
Anatomic and Biologic Staging of Breast Disease with MRI$429,775
R01 · FY2006 · CA · contact PI
MRI For Staging DCIS and Assessing Response to Treatment$400,666
R01 · FY2006 · CA · contact PI
NONINVASIVE IMAGING OF ERBB RECEPTOR LIGAND INTERACTIONS$158,272
U54 · FY2006 · CA · contact PI
ANATOMIC AND BIOLOGIC STAGING OF BREAST DISEASE WITH MRI$251,178
R01 · FY2005 · CA
ANATOMIC AND BIOLOGIC STAGING OF BREAST DISEASE WITH MRI$249,990
R01 · FY2004 · CA
ANATOMIC AND BIOLOGIC STAGING OF BREAST DISEASE WITH MRI$253,553
R01 · FY2003 · CA
ANATOMIC AND BIOLOGIC STAGING OF BREAST DISEASE WITH MRI$254,740
R01 · FY2002 · CA
NONINVASIVE IMAGING OF ERBB RECEPTOR LIGAND INTERACTIONS$158,272
U54 · FY2002 · CA
ANATOMIC AND BIOLOGIC STAGING OF BREAST DISEASE WITH MRI$253,078
R01 · FY2001 · CA
NONINVASIVE IMAGING OF ERBB RECEPTOR LIGAND INTERACTIONS$0
U54 · FY2001 · CA